A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer

Inclusion Criteria: All of the following must apply: * Histologically proven adenocarcinoma of the stomach or gastro-oesophageal junction that is: 1. completely resected with negative margins 2. Stage T3,4 and/or N1,2 patients who have undergone a D2 nodal dissection can be entered on the study at the discretion of the treating clinician. * Age greater than or equal to 18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2 * Adequate organ function defined as follows: * Bone marrow: Haemoglobin greater than or equal to 90 g/L; Neutrophil count greater than or equal to 1.5 x 10\^9 /L; Platelet count greater than or equal to 100 x 10\^9 /L * Hepatic: Serum bilirubin less than or equal to 1.5 x ULN; AST and/or ALT less than or equal to 3.0 x ULN; * Renal: Serum creatinine less than or equal to 0.150 mmol/L, and calculated creatinine clearance greater than or equal to 50mL/min. * Adequate oral nutrition (intake greater than or equal to 1500 calories/day). This is to be assessed by a dietician prior to commencing treatment. * Disease which can be radically treated to 45 Gy with standard fractionation. * Patient able to be treated with infusional 5-fluorouracil (5-FU) and ECF chemotherapy. * Written informed consent Exclusion Criteria: None of the following must apply: * Evidence of metastatic disease. * Prior chemotherapy or radiotherapy * Patients with other significant underlying medical conditions that may be aggravated by the study treatment or are not controlled. * Pregnant or lactating females or female patients of childbearing potential who have not been surgically sterilized or are without adequate contraceptive measures. * Cardiac failure (relevant to the use of epirubicin): * Patients with myocardial infarction within the last 6 months; * Patients with New York Heart Association class III/IV congestive heart failure